Background
- While treatment and management of TNBC has improved, there is a need for novel prognostic biomarkers to better inform outcomes and guide therapeutic options.
- ILF2 is a poorly characterized protein with pleiotropic functions that is highly expressed in TNBC.
- Here we evaluated the associations of ILF2 with 1) genomic and transcriptomic data, 2) tumor microenvironment (TME), and 3) clinical outcomes in TNBC.